Global healthcare is rapidly shifting towards minimally invasive procedures and digital transformation (DX) to enhance patient outcomes and operational efficiency. Regulatory bodies and patient advocacy groups are also pushing for significant reductions in radiation exposure and contrast agent use. This technology aligns perfectly with these trends, offering a solution that improves surgical precision, reduces risks, and lowers costs, making it a critical innovation for hospitals and medical device manufacturers worldwide.
Reduces Radiation & Contrast Agent Use by ~70%: Estimates 3D shapes from a single 2D image, significantly lowering patient and physician radiation exposure and contrast agent usage compared to conventional multi-image reconstruction or continuous fluoroscopy.
Enhances Procedure Safety & Precision by ~20%: Improves intuitive understanding of endovascular device position and movement with near real-time 3D shape recognition, reducing complication risks and increasing procedure success rates by ~20%.
Provides Skill-Independent Treatment Support: Enables less experienced physicians to accurately grasp wire 3D shapes, shortening training periods and elevating the overall technical standard in medical settings.
This patent protects an image processing apparatus, program, and method for 3D visualization from a single 2D image. It demonstrates strong differentiation from existing technologies, having overcome rigorous examination without rejection despite 9 cited prior art documents, indicating robust and stable claim strength across various business models.
A licensee could build additional IP in areas such as AI-driven predictive analytics for procedural outcomes, integration with augmented reality (AR) for real-time surgical guidance, or specialized hardware for enhanced image acquisition beyond standard X-ray systems.
For a hospital performing 3,000 endovascular procedures annually, assuming an average contrast agent cost of ~$333/procedure (AI est.) and a 20% increase in operating room utilization due to reduced fluoroscopy time: contrast agent cost reduction of ~$700K/year (AI est.) ($333/procedure × 3,000 procedures × 70% reduction) plus revenue increase from shorter procedure times of ~$350K/year (AI est.) ($3.5M annual revenue × 10% increase). This totals an estimated annual economic benefit of ~$1.0M/year (AI est.). This calculation does not include the health risk reduction benefits for medical staff due to reduced radiation exposure.
X: Real-time 3D Visualization Accuracy
Y: Ease of Clinical Integration